2024
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS
Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.Peer-Reviewed Original ResearchDiagnosed AMLSurvival benefitManagement of acute myeloid leukemiaDevelopment of oral therapiesIsocitrate dehydrogenase inhibitorsNewly diagnosed AMLManagement of adult patientsPost-transplant maintenanceAcute myeloid leukemiaSingle-arm studyExcellent response ratesIDH inhibitorsRelapsed AMLHypomethylating agentsInhibitor therapyMyelodysplastic syndromeOral therapyCombination therapyPost-transplantMyeloid leukemiaImproved survivalSingle-armAdult patientsAzacitidineRandomized study
2021
Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
Grenet J, Jain A, Burkart M, Waksal J, Famulare C, Numan Y, Stahl M, Mckinnell Z, Ball B, Ma X, Christos P, Ritchie E, Samuel M, Kaner J, Lee S, Goldberg A, Dinner S, Sweet K, Roboz G, Desai P. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood 2021, 138: 32. DOI: 10.1182/blood-2021-145947.Peer-Reviewed Original ResearchRelapse free survivalEntity's Board of DirectorsCPX-351Overall survivalFrontline therapyTreated ptsMultivariate analysisRetrospective studySurvival advantageSubgroup analysisMedian relapse free survivalMulti-center retrospective studyMultivariate Cox proportional hazards regression analysisCox proportional hazards regression analysisVariability of treatment responseMultivariate subgroup analysisNewly diagnosed AMLKaplan-Meier survival analysisMultivariate logistic regression analysisProportional hazards regression analysisMulticenter retrospective studyLog-rank testAcute myeloid leukemiaHazards regression analysisPrimary outcome variable
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply